We are live on ! Find out more
SBIO icon

ALPS Medical Breakthroughs ETF

48 hedge funds and large institutions have $44.6M invested in ALPS Medical Breakthroughs ETF in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 20 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

253% more call options, than puts

Call options by funds: $258K | Put options by funds: $73K

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

51% more capital invested

Capital invested by funds: $29.5M → $44.6M (+$15.1M)

10.52% more ownership

Funds ownership: 29.74%40.26% (+11%)

9% more funds holding

Funds holding: 4448 (+4)

85% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 20

Holders
48
Holders Change
+4
Holders Change %
+9.09%
% of All Funds
0.77%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
3
Reduced
20
Closed
4
Calls
$258K
Puts
$73K
Net Calls
+$185K
Net Calls Change
-$93K
Name Holding Trade Value Shares
Change
Change in
Stake
Northwestern Mutual Wealth Management
51
Northwestern Mutual Wealth Management
Wisconsin
-$15K -500 Closed
SBL
52
Sargent Bickham Lagudis
Colorado
-$3K -100 Closed

SBIO Hedge Fund Activity: Q4 2022 in Review

48 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ALPS Medical Breakthroughs ETF (SBIO) for Q4 2022, worth a combined $44.6M — up 51% from $29.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SBIO positions and 4 closed out — a net gain of 5 holders — while 3 added to existing stakes and 20 trimmed.

The largest buyer was Davenport & Co, opening a new position worth an estimated $18.4M. The largest seller was UBS Group, cutting an estimated $2.6M.

  • 48 institutional investors held ALPS Medical Breakthroughs ETF (SBIO) as of Q4 2022, up from 44 in Q3 2022.
  • Funds reported $44.6M of ALPS Medical Breakthroughs ETF stock for Q4 2022, up 51% quarter-over-quarter.
  • 9 funds opened new ALPS Medical Breakthroughs ETF positions in Q4 2022 and 4 closed out, a net change of +5 holders.
  • The largest ALPS Medical Breakthroughs ETF buyer in Q4 2022 was Davenport & Co, an estimated $18.4M added.
  • The largest ALPS Medical Breakthroughs ETF seller in Q4 2022 was UBS Group, an estimated $2.6M sold.

Based on aggregated 13F filings for Q4 2022.